{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:58Z","timestamp":1762459798655,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bone.2019.115118","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T11:46:01Z","timestamp":1572781561000},"page":"115118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-4412","authenticated-orcid":false,"given":"Rachel K.","family":"Surowiec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren F.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferrous S.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Schlecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basma M.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Wojtys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Caird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Kozloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2019.115118_bib0005","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2019.115118_bib0010","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bone.2019.115118_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trsl.2016.11.005","article-title":"Osteogenesis imperfecta: new genes reveal novel mechanisms in bone dysplasia","volume":"181","author":"Kang","year":"2017","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/JPEM.2002.15.2.163","article-title":"Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response","volume":"15","author":"Zacharin","year":"2002","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0025","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.115118_bib0040","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.115118_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0060","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115118_bib0070","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bone.2019.115118_bib0080","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1056\/NEJMc1402396","article-title":"Romosozumab in postmenopausal women with osteopenia","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2019.115118_bib0090","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115118_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115118_bib0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0110","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(-\/-) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2019.115118_bib0115","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115118_bib0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2019.115118_bib0125","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115118_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3647","article-title":"Osteogenesis Imperfecta: A Need to Understand Divergent Treatment Outcomes in a Disorder Rich in Heterogeneity","author":"Kozloff","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.115118_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.20429","article-title":"Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans","volume":"28","author":"Marini","year":"2007","journal-title":"Hum. Mutat."},{"issue":"7","key":"10.1016\/j.bone.2019.115118_bib0140","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/jbmr.3421","article-title":"Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl\/+ osteogenesis imperfecta mouse model","volume":"33","author":"Olvera","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115118_bib0145","first-page":"31","article-title":"[Report]","volume":"27","author":"Isaacson","year":"1962","journal-title":"Mouse News Lett"},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nprot.2007.25","article-title":"Establishment of human tumor xenografts in immunodeficient mice","volume":"2","author":"Morton","year":"2007","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc3944","article-title":"Examining the utility of patient-derived xenograft mouse models","volume":"15","author":"Aparicio","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bone.2019.115118_bib0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-59745-104-8_7","article-title":"Ossicle and vossicle implant model systems","volume":"455","author":"Pettway","year":"2008","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0165","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bone.2007.11.017","article-title":"Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation","volume":"42","author":"Pettway","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115118_bib0170","first-page":"62","article-title":"A threshold selection method from gray-level histograms","volume":"91","author":"N","year":"1979","journal-title":"IEEE Trans. Syst. Man. Cybern."},{"key":"10.1016\/j.bone.2019.115118_bib0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","article-title":"Tissue processing and hematoxylin and eosin staining","volume":"1180","author":"Feldman","year":"2014","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S8756-3282(99)00194-5","article-title":"Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach","volume":"25","author":"Hauge","year":"1999","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF01623458","article-title":"Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry","volume":"7","author":"Ballanti","year":"1997","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bone.2019.115118_bib0195","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.bone.2019.115118_bib0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Li","year":"2018","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bone.2019.115118_bib0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2017.11.003","article-title":"Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists","volume":"107","author":"Holdsworth","year":"2018","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/dvdy.20603","article-title":"Buried alive: how osteoblasts become osteocytes","volume":"235","author":"Franz-Odendaal","year":"2006","journal-title":"Dev. Dyn."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0215","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ar.1092220204","article-title":"Lifetime of the osteoblast in mouse periodontium","volume":"222","author":"McCulloch","year":"1988","journal-title":"Anat. Rec."},{"key":"10.1016\/j.bone.2019.115118_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1083\/jcb.19.1.33","article-title":"Cell population kinetics of an osteogenic tissue. Ii","volume":"19","author":"Owen","year":"1963","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bone.2019.115118_bib0230","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1302\/0301-620X.42B4.824","article-title":"Cell division in endochondral ossification. A study of cell proliferation in rat bones by the method of tritiated thymidine autoradiography","volume":"42B","author":"Kember","year":"1960","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.bone.2019.115118_bib0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1083\/jcb.14.3.357","article-title":"Cell proliferation and specialization during endochondral osteogenesis in young rats","volume":"14","author":"Young","year":"1962","journal-title":"J. Cell Biol."},{"issue":"23","key":"10.1016\/j.bone.2019.115118_bib0240","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.bone.2019.115118_bib0245","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bone.2019.115118_bib0250","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1369\/jhc.2008.950527","article-title":"Matrix mineralization as a trigger for osteocyte maturation","volume":"56","author":"Irie","year":"2008","journal-title":"J. Histochem. Cytochem."},{"issue":"6","key":"10.1016\/j.bone.2019.115118_bib0255","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.bone.2019.115118_bib0260","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bone.2005.02.015","article-title":"Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone","volume":"36","author":"Pettway","year":"2005","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0265","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0736-0266(03)00042-1","article-title":"Skeletal homeostasis in tissue-engineered bone","volume":"21","author":"Schneider","year":"2003","journal-title":"J. Orthop. Res."},{"year":"2013","series-title":"Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteroporosis","author":"Marcus","key":"10.1016\/j.bone.2019.115118_bib0270"},{"issue":"3","key":"10.1016\/j.bone.2019.115118_bib0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/17453678909149289","article-title":"Repair of bone defects with marrow cells and porous ceramic. Experiments in rats","volume":"60","author":"Ohgushi","year":"1989","journal-title":"Acta Orthop. Scand."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jor.1100090402","article-title":"Culture-expanded human periosteal-derived cells exhibit osteochondral potential in vivo","volume":"9","author":"Nakahara","year":"1991","journal-title":"J. Orthop. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0285","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","article-title":"Wnt signaling as a therapeutic target for bone diseases","volume":"13","author":"Hoeppner","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.bone.2019.115118_bib0290","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0295","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.115118_bib0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0305","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jbmr.1807","article-title":"Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading","volume":"28","author":"Spatz","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jbm4.10025","article-title":"Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice","volume":"2","author":"Williams","year":"2018","journal-title":"Jbmr Plus"},{"issue":"8","key":"10.1016\/j.bone.2019.115118_bib0315","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115118_bib0320","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajpa.22150","article-title":"Brief communication: the effects of disuse on the mechanical properties of bone: what unloading tells us about the adaptive nature of skeletal tissue","volume":"149","author":"Schlecht","year":"2012","journal-title":"Am. J. Phys. Anthropol."},{"issue":"1","key":"10.1016\/j.bone.2019.115118_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2004.03.022","article-title":"What is the normal rate of bone remodeling?","volume":"35","author":"Parfitt","year":"2004","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:46:18Z","timestamp":1757612778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219304119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":65,"alternative-id":["S8756328219304119"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115118","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115118"}}